Technological advances are speeding the development of digital measures and endpoints throughout drug development and across therapeutic areas and patient populations. While regulators encourage stakeholders to pursue patient-centric approaches, few actionable guidances or standards exist.
Evidation, Elektra Labs, and the Digital Medicine Society teamed up to share their thoughts on building a digital future of health measurement that effectively and efficiently serves patients, regulators, and clinical decision-makers. Read the full piece in Global Forum.
Technological advances are speeding the development of digital measures and endpoints throughout drug development and across therapeutic areas and patient populations. While regulators encourage stakeholders to pursue patient-centric approaches, few actionable guidances or standards exist.
Evidation, Elektra Labs, and the Digital Medicine Society teamed up to share their thoughts on building a digital future of health measurement that effectively and efficiently serves patients, regulators, and clinical decision-makers. Read the full piece in Global Forum.
Technological advances are speeding the development of digital measures and endpoints throughout drug development and across therapeutic areas and patient populations. While regulators encourage stakeholders to pursue patient-centric approaches, few actionable guidances or standards exist.
Evidation, Elektra Labs, and the Digital Medicine Society teamed up to share their thoughts on building a digital future of health measurement that effectively and efficiently serves patients, regulators, and clinical decision-makers. Read the full piece in Global Forum.
Evidation and the Duke Big Ideas Lab have announced a partnership that aims to find ways to both increase representation of underserved populations and improve adherence among all participants in digital health studies.
The organizations are working together to build an analytic structure that will be available to other digital health researchers, helping to better predict study participation, adherence, and retention. Click below to read more about the project, led by Iredia M. Olaye, PhD, MSc, MHA, of Covered By Group and Evidation, in HealthLeaders.
Thanks to everyone who took the time to meet with us in San Francisco at this year’s J.P. Morgan Annual Conference and its surrounding events. Our team looks forward to staying in touch and helping you produce better health outcomes in 2023!
Get to know your Evidation team
Bertina Yen, Evidation's Senior Vice President of People & Community
Bertina Yen is Evidation's Senior Vice President of People & Community, where she is responsible for the end-to-end employee experience and building a community that supports everyone's ability to show up as their authentic selves and perform their best work. Prior to joining Evidation, Bertina served as EVP overseeing clinical teams, product management, marketing, and product development at Zynx Health, driving development of evidence-based clinical decision support solutions that improve health and financial outcomes.
Bertina received her BAS from Stanford, then completed her MD and residency in internal medicine at UC San Diego. She also holds an MPH in health services administration from UCLA.
Bertina is the resident DJ at Evidation and sources the music that is played during the All-Employee Meetings. Outside of work, she enjoys hiking, traveling, and watching anything with a live audience (sporting events, plays, movies). She also starts every morning by completing at least one crossword puzzle!
Technological advances are speeding the development of digital measures and endpoints throughout drug development and across therapeutic areas and patient populations. While regulators encourage stakeholders to pursue patient-centric approaches, few actionable guidances or standards exist.
Evidation, Elektra Labs, and the Digital Medicine Society teamed up to share their thoughts on building a digital future of health measurement that effectively and efficiently serves patients, regulators, and clinical decision-makers. Read the full piece in Global Forum.
Technological advances are speeding the development of digital measures and endpoints throughout drug development and across therapeutic areas and patient populations. While regulators encourage stakeholders to pursue patient-centric approaches, few actionable guidances or standards exist.
Evidation, Elektra Labs, and the Digital Medicine Society teamed up to share their thoughts on building a digital future of health measurement that effectively and efficiently serves patients, regulators, and clinical decision-makers. Read the full piece in Global Forum.
Technological advances are speeding the development of digital measures and endpoints throughout drug development and across therapeutic areas and patient populations. While regulators encourage stakeholders to pursue patient-centric approaches, few actionable guidances or standards exist.
Evidation, Elektra Labs, and the Digital Medicine Society teamed up to share their thoughts on building a digital future of health measurement that effectively and efficiently serves patients, regulators, and clinical decision-makers. Read the full piece in Global Forum.
Technological advances are speeding the development of digital measures and endpoints throughout drug development and across therapeutic areas and patient populations. While regulators encourage stakeholders to pursue patient-centric approaches, few actionable guidances or standards exist.
Evidation, Elektra Labs, and the Digital Medicine Society teamed up to share their thoughts on building a digital future of health measurement that effectively and efficiently serves patients, regulators, and clinical decision-makers. Read the full piece in Global Forum.
